Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC).Karen DeSouza, Sarah Khan, Maria Diossy et al.|Journal of Clinical Oncology|2021Cited by 3